Phase 3 Completed N=14 Treatment

Escitalopram (Lexapro) for Depression MS or ALS

Depression · Multiple Sclerosis · Amyotrophic Lateral Sclerosis

Source: ClinicalTrials.gov NCT00965497 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2011

Primary outcomePrimary: Hamilton Depression Scale (HAM-D 17). — 15 depression severity — p=0.01

Summary

The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.

Outcome Measures

Outcome	Result	p-value
PRIMARY Hamilton Depression Scale (HAM-D 17).	15	0.01 sig
SECONDARY McGill Quality of Life Scale (MQOL)	5	—

Eligibility Criteria

Inclusion Criteria

Patients between 18 and 70 years of age with documented ALS or MS,
DSM-IV episode of non-psychotic Major Depression,
≥14 score on the 17-item HAM-D,
Ability to give informed consent.

Exclusion Criteria

History of psychotic disorders,
Psychotic depression,
Bipolar depression,
Suicide risk,
History of substance abuse in the previous 6 months,
History of unstable medical disorders,
Pregnancy or planning for pregnancy,
Severity of ALS or MS that limits participating in the study protocol.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00965497). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.